Effective homocysteine-lowering vitamin B treatment in peritoneal dialysis patients

Peritoneal Dialysis International

Volumn 24, Issue 4, 2004, Pages 373-377

  Righetti, Marco ^a   Tommasi, Adalberto ^a   Lagona, Cinzia ^a   La Rosa, Lucia ^a   Uccellini, Mario ^a   Sessa, Adalberto ^a  

^a DESIO HOSPITAL   (Italy)

Author keywords

B vitamins; Cardiovascular disease; Homocysteine

Indexed keywords

ANTICONVULSIVE AGENT; CYANOCOBALAMIN; ESTROGEN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE; THEOPHYLLINE; VITAMIN B GROUP;

ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CLEARANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; FOLIC ACID BLOOD LEVEL; HUMAN; HYPERHOMOCYSTEINEMIA; MATHEMATICAL COMPUTING; MEMBRANE PERMEABILITY; MORBIDITY; MORTALITY; NORMAL VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; VITAMIN BLOOD LEVEL;

EID: 4444308494     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080402400413     Document Type: Article

References (31)

1. Chauveau P, Chadefaux B, Coude M, Aupetit J, Hannedouche T, Kamoun P, et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int Suppl 1993; 41:S72-7.
2. Bachmann J, Tepel M, Raidt H, Riezler R, Graefe U, Langer K, et al. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 1995; 6:121-5.
3. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56;111-28.
4. United States Renal Data System. USRDS 1998 Annual Data Report. Bethesda, MD: National Institute of Diabetes and Kidney Diseases; 1999: 63-90.
5. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 356:147-52.
6. Bostom AG, Culleton BF. Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol 1999; 10: 891-900.
7. Perna AF, Ingrosso D, Satta E, Romano M, Cimmino A, Galletti P, et al. Metabolic consequences of hyperhomocysteinemia in uremia. Am J Kidney Dis 2001; 38(Suppl 1): S85-S90.
8. Czeizel AE. Folic acid in the prevention of neural tube defect. J Pediatr Gastroenterol Nutr 1995; 20:4.
9. Bostom AG, Shemin D, Lapane KL, Sutherland P, Nadeau MR, Wilson PW, et al. Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis 1996; 123:193-202.
10. Quinlivan EP, McPartlin J, McNulty H, Ward M, Strani JJ, Weir DG, et al. Importance of both folic acid and vitamin B12 in reduction of risk of vascular disease. Lancet 2002; 359:227-8.
11. Shemin D, Bostom AG, Selhub J. Treatment of hyperhomocysteinemia in end-stage renal disease. Am J Kidney Dis 2001; 38(Suppl 4):S91-4.
12. House AA, Wells GA, Donnelly JG, Nadler SP, Hebert PC. Randomized trial of high-flux vs low-flux hemodialysis: effects on homocysteine and lipids. Nephrol Dial Transplant 2000; 15:1029-34.
13. Van Telligen A, Grooteman MP, Bartels PC, Van Limbeek J, Van Guldener C, ter Wee PM, et al. Long-term reduction of plasma homocysteine levels by super-flux dialyzers in hemodialysis patients. Kidney Int 2001; 59:342-7.
14. Van Guldener C, Janssen MJ, Lambert J, ter Wee PM, Donker AJ, Stehouwer CD. Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: no change in endothelial function after long-term therapy. Perit Dial Int 1998; 18:282-9.
15. De Vecchi AF, Patrosso C, Novembrino C, Finazzi S, Colucci P, De Franceschi M, et al. Folate supplementation in peritoneal dialysis patients with normal erythrocyte folate: effect on plasma homocysteine. Nephron 2001; 89:297-302.
16. Vilaseca MA, Monros E, Artuch R, Colome C, Farre C, Valls C, et al. Anti-epileptic drug treatment in children: hyperhomocysteinemia, B-vitamins and the 677C→T mutation of the methylenetetrahydrofolate reductase gene. Eur J Paediatr Neurol 2000; 4:269-77.
17. Giri S, Thompson PD, Taxel P, Contois JH, Otvos J, Allen R, et al. Oral estrogen improves serum lipids, homocysteine and fibrinolysis in elderly men. Atherosclerosis 1998; 138:403.
18. Ubbink JB, van der Merwe A, Delport R, Allen RH, Stabler SP, Riezler R, et al. The effect of a subnormal vitamin B6 status on homocysteine metabolism. J Clin Invest 1996; 98:177-84.
19. Suliman ME, Qureshi AR, Barany P, Stenvinkel P, Filho JC, Anderstam B, et al. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int 2000; 57:1727-35.
20. Watson PE, Watson ID, Batt RD. Total body water volumes for adult males and females estimated from simple anthropometric measurements. Am J Clin Nutr 1980; 33:27-39.
21. Heimbürger O, Wang T, Lonnqvist F, Stenvinkel P. Peritoneal clearance of leptin in CAPD patients: impact of local insulin administration. Nephrol Dial Transplant 1999; 14:723-7.
22. Johnson DW, Kay TD, Vesey DA, Isbel N, Campbell SB, Hawley CM. Peritoneal homocysteine clearance is inefficient in peritoneal dialysis patients. Perit Dial Int 2000; 20:766-71.
23. Twardowski ZJ, Nolph KD, Khanna R, Prowant BF, Ryan LP, Moore HL. Peritoneal equilibration test. Perit Dial Bull 1987; 7:138-47.
24. Righetti M, Ferrario GM, Milani S, Serbelloni P, La Rosa L, Uccellini M, et al. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. Med Sci Monit 2003; 9(4): P119-24.
25. Moustapha A, Gupta A, Robinson K, Arheart K, Jacobsen DW, Schreiber MJ, et al. Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. Kidney Int 1999; 55:1470-5.
26. Ashfield-Watt PA, Whiting JM, Clark ZE, Moat SJ, Newcombe RG, Burr ML, et al. A comparison of the effect of advice to eat either '5-a-day' fruit and vegetables or folic acid-fortified foods on plasma folate and homocysteine. Eur J Clin Nutr 2003; 57:316-23.
27. Willcox JK, Catignani GL, Lazarus S. Tomatoes and cardiovascular health. Crit Rev Food Sci Nutr 2003; 43:1-18.
28. Sunder-Plassmann G, Fodinger M, Buchmayer H, Papagiannopoulos M, Wojcik J, Kletzmayr J, et al. Effect of high dose folic acid therapy on hyperhomocysteinemia in dialysis patients: results of the Vienna Multicenter Study. J Am Soc Nephrol 2000; 11: 1106-16.
29. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease. Plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989; 114: 473-501.
30. Descombes E, Hanck AB, Fellay G. Water soluble vitamins in chronic hemodialysis patients and for supplementation. Kidney Int 1993; 43:1319-28.
31. Schnyder G, Roffi M, Pin R, Flammer Y, Lange H, Eberli FR, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345:559-600.